Immunotherapy drugs like Keytruda and Opdivo work by changing the way the immune system reacts to cancer and giving the immune system the ability to fight against cancer. However, not all cancer patients have access to these drugs, it depends on the type of cancer they have.

Professor Michael Boyer, Chris O’Brien Lifehouse Chief Clinical Officer, talked to Today Tonight Adelaide about the importance of having a system in Australia that values equity of access, that is where people that need treatments are able to get them based on clinical need rather than wealth.